ROS1 rearrangement is found in 0.9%-2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. This review summarizes the current knowledge on ROS1 rearrangements in NSCLCs, including the mechanisms of ROS1 oncogenicity, epidemiology of ROS1-positive tumors, methods for detecting rearrangements, molecular characteristics, therapeutic agents, and mechanisms of drug resistance.
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Hubei, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Yang Xin,Tang Zhe,Li Jing,et al.Progress of non-small-cell lung cancer with ROS1 rearrangement[J].FRONTIERS IN MOLECULAR BIOSCIENCES.2023,10:doi:10.3389/fmolb.2023.1238093.
APA：
Yang, Xin,Tang, Zhe,Li, Jing,Jiang, Jizong&Liu, Yue.(2023).Progress of non-small-cell lung cancer with ROS1 rearrangement.FRONTIERS IN MOLECULAR BIOSCIENCES,10,
MLA：
Yang, Xin,et al."Progress of non-small-cell lung cancer with ROS1 rearrangement".FRONTIERS IN MOLECULAR BIOSCIENCES 10.(2023)
